Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K. Gopal, Gilles Salles, Georg Heß et al.|Journal of Clinical Oncology|2018Cited by 103
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Blood|2016Cited by 9